# The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

> **NCT04981145** · PHASE4 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 78 (estimated)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** Iguratimod Tablets
- **DRUG:** Hydroxychloroquine Sulfate Tablets

## Key facts

- **NCT ID:** NCT04981145
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-14
- **Primary completion:** 2024-12
- **Final completion:** 2025-07
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04981145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04981145, "The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04981145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*